Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) will be the Headline Sponsor for Wonderland Psychedelic Conference, taking place in Miami from November 3-5th, 2022
  • Wonderland is the world’s largest conference in the psychedelic medicine sector
  • Some of the leading founders, investors, therapists, practitioners, researchers, thought leaders, innovators, and media from around the globe attend this event
  • Algernon is a clinical-stage drug development company which focuses on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough
  • Algernon Pharmaceuticals Inc. (AGN) is down 0.65 per cent, trading at C$6.11 per share at 12:11 pm ET

Algernon Pharmaceuticals (AGN) will be the Headline Sponsor for Wonderland Psychedelic Conference, taking place in Miami from November 3-5th, 2022.

Wonderland is the world’s largest conference in the psychedelic medicine sector. It provides an opportunity to discover the world of psychedelic medicine. Some of the leading founders, investors, therapists, practitioners, researchers, thought leaders, innovators, and media from around the globe attend this event.

Christopher J. Moreau, CEO of Algernon, commented on the announcement.

“We are delighted to be the Headline Sponsor for the Wonderland 2022 event. We have the opportunity to build a greater awareness of Algernon and our DMT stroke research program within the many different facets of the psychedelic medicine world.”

Algernon has established a clinical research program for treating stroke focused on AP-188 (“N, N-Dimethyltryptamine or DMT”). It’s a known psychedelic compound that is part of the tryptamine family. Other drugs in the tryptamine family include psilocybin and psilocin.

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug. It produces effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

The company has been laying the clinical groundwork to be the first company globally to investigate sub-psychedelic doses of DMT as a possible treatment for stroke. It is planning to begin a Phase 1 clinical trial in Q4 2022.

Algernon is a clinical-stage drug development company which focuses on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough.

Algernon Pharmaceuticals Inc. (AGN) is down 0.65 per cent, trading at C$6.11 per share at 12:11 pm ET.


More From The Market Herald

" Diagnos (TSXV:ADK) closes non-brokered private placement

Diagnos (ADK) has closed its non-brokered private placement for gross proceeds of $500,000.
NurExone Exosomes

" NurExone (TSXV:NRX) reports Q3 2022 financial results & provides corporate update

NurExone Biologic (NRX) reported its financial results for the quarter ended September 30, 2022.

" Wellteq (CSE:WTEQ) announces shareholder approval for plan of arrangement with AHI

Wellteq Digital Health (WTEQ) has announced that holders of its common shares have approved its plan of arrangement.

" Empower Clinics (CSE:EPW) names new General Manager of Medisure Labs

Empower Clinics (EPW) has appointed Eric Christian as the new General Manager of its medical diagnostics laboratory business, Medisure Labs.